CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
We are very excited to launch our new website! Please take a few moments to click around and explore...
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...